To verify our conclusion, we selected additional human pancreatic cancer cell lines including BxPC-3 (KRAS wildtype, TP53 mutant) and Capan-2 (KRAS mutant, TP53 mutant, RNF43 mutant) for an SEMA6C overexpression study. This evidence concerns the gene KRAS and familial pancreatic carcinoma.